For years the standard treatment for obstructive sleep apnea (OSA) was a machine, not a molecule: continuous positive airway pressure (CPAP), or more broadly positive airway pressure (PAP). That changed at the end of 2024, when Zepbound (tirzepatide) became the first drug ever approved to treat OSA. It is a genuine, specific indication — and, like most things in this space, it is widely oversimplified. Here is precisely what was approved, what the trials showed, and where the honest limits sit.
A real approval, precisely stated
On December 20, 2024, the FDA approved Zepbound (tirzepatide) to treat moderate-to-severe obstructive sleep apnea in adults with obesity, to be used alongside a reduced-calorie diet and increased physical activity.[2] The precise wording matters. The indication is not “OSA” in the abstract; it is moderate-to-severe OSA in adults with obesity. Tirzepatide is the same dual GIP/GLP-1 receptor agonist already marketed for weight management and, as Mounjaro, for type 2 diabetes — so if you want the deeper pharmacology, our tirzepatide versus semaglutide comparison covers how the two incretin classes differ.
The SURMOUNT-OSA trials: what they measured
The approval rested on SURMOUNT-OSA, reported as two Phase 3, double-blind, randomized, placebo-controlled trials in a single 2024 New England Journal of Medicine paper. Both enrolled adults with moderate-to-severe OSA and obesity. Trial 1 studied people not receiving PAP at baseline; trial 2 studied people who were already on PAP. Participants were randomized 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks.[1] The primary endpoint was the change in the apnea-hypopnea index (AHI) — the number of apneas and hypopneas per hour of sleep, and the standard measure of OSA severity.
The magnitude of the AHI reduction
At baseline, participants were seriously affected: mean AHI was 51.5 events/hour in trial 1 and 49.5 in trial 2 (an AHI at or above 30 defines severe OSA).[1] At week 52, the mean AHI fell by about 25.3 events/hour on tirzepatide versus 5.3 on placebo in trial 1 — an estimated treatment difference of roughly 20 events/hour. In trial 2 (participants on PAP), AHI fell by about 29.3 events/hour on tirzepatide versus 5.5 on placebo, a difference of about 24 events/hour.[1] Both were highly statistically significant. In plain terms, average severity dropped from severe toward the mild-to-moderate range — a clinically meaningful shift, not a marginal one. Prespecified secondary endpoints, including hypoxic burden, high-sensitivity CRP, systolic blood pressure and patient-reported sleep measures, also improved with tirzepatide.[1]
Why it works: the weight-loss mechanism
The mechanism is not a direct effect on the airway muscles — it is weight loss. Excess adiposity, particularly around the neck and upper airway and within the abdomen, is a central driver of OSA: it narrows and destabilizes the airway and increases the mechanical work of breathing during sleep. Reduce that adiposity and the airway loads less, so apneas and hypopneas fall. That is why the AHI benefit tracks with the weight lost, and why the indication is anchored to obesity. The tolerability profile is the familiar incretin one — the most frequent adverse events were gastrointestinal and mostly mild to moderate,[1] which we cover in depth in our guide to Zepbound side effects.
Do other GLP-1s work for sleep apnea?
Zepbound holds the approval, but it is not the only drug in the class with sleep-apnea data, and the class-level picture is now reasonably well quantified. A 2026 meta-analysis pooling four randomized trials of GLP-1 receptor agonists against placebo in adults with OSA found a significant reduction in the apnea-hypopnea index of 13.89 events per hour, alongside 12.46 kg of weight loss and a 4.86 mm Hg fall in systolic blood pressure.[3] The effect looks like a property of substantial weight loss rather than something unique to tirzepatide.
The more useful comparison is against the treatment people are hoping to escape. A network meta-analysis of 34 randomized trials in 3,964 participants ranked CPAP, GLP-1 receptor agonists and their combination against no active intervention. CPAP produced the largest reduction in AHI — 22.17 events per hour — and the only meaningful improvement in daytime sleepiness on the Epworth scale. The GLP-1 arms did what they do well: liraglutide reduced body-mass index and HbA1c, where CPAP showed no meaningful metabolic effect, and liraglutide plus CPAP achieved the greatest BMI reduction of all.[4] Certainty of evidence was graded moderate for CPAP on respiratory and sleepiness outcomes, and moderate for GLP-1 receptor agonists on BMI and HbA1c.
Read together, those two analyses point somewhere more interesting than “a drug instead of a machine.” They fix different things: the machine is better at the breathing, the drug is better at the metabolic disease underneath it, and the combination beat either alone on weight. That is an argument for combining them, not substituting one for the other.
The honest limits: not a blanket CPAP replacement
Three caveats keep this accurate. First, this is not a universal substitute for PAP. Trial 2 specifically studied people who stayed on PAP, and even on tirzepatide the mean AHI did not fall to zero — meaningful residual apnea often remained. Whether an individual can reduce or stop PAP is a clinical decision made with a sleep specialist and follow-up testing, not an assumption. Second, the benefit is tied to weight loss, so it is most relevant to adults with obesity and depends on sustained treatment and lifestyle change; the approved use is explicitly alongside diet and activity. Third, this is real medication with real cost and access hurdles — see our notes on what Zepbound costs and how to get Zepbound, and how it stacks up against the semaglutide option in Zepbound versus Wegovy.
The honest bottom line
Zepbound for OSA is a legitimate first: the first drug approved for a condition long treated only with a machine, backed by two Phase 3 trials showing large, significant reductions in AHI over a year. But “first drug for sleep apnea” is a precise claim, not a blanket one. It is approved for moderate-to-severe OSA in adults with obesity, its benefit is mediated by weight loss, and it complements PAP rather than automatically replacing it. For the right patient, that is a genuinely new and useful option — best pursued as part of a plan set with a clinician, not as a self-directed swap for a CPAP machine.